Please enable JavaScript to continue using this application.

Compare $OTLK vs $RNA | Chartloom

Compare

$OTLK vs $RNA

Outlook Therapeutics Inc · Atrium Therapeutics Inc

OTLK

Outlook Therapeutics Inc

RNA

Atrium Therapeutics Inc

Compare $OTLK vs $RNA

Comparing Outlook Therapeutics Inc and Atrium Therapeutics Inc

OTLKOutlook Therapeutics Inc

RNAAtrium Therapeutics Inc

OTLKOutlook Therapeutics Inc

Market cap

$112M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.58x

Rev growth (TTM)

-171.2%

YTD performance

-9.3%

52W performance

-52.5%

FCF yield

-50.1%

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

OTLK

RNA

Detailed metrics comparison

OTLK

Outlook Therapeutics Inc

RNA

Atrium Therapeutics Inc

Market Cap

OTLK$112M

RNA$144M

Enterprise Value

OTLK$119M

RNA$71M

Price

OTLK$0.60

RNA$8.40

P/E Ratio

OTLKN/A

RNAN/A

P/S Ratio

OTLK0.00x

RNA3.48x

EV/Sales

OTLK1,109.27x

RNA1.73x

EV/EBITDA

OTLK0.00x

RNA0.00x

P/B Ratio

OTLK13.76x

RNA0.63x

P/FCF Ratio

OTLKN/A

RNAN/A

EV/FCF

OTLK-2.12x

RNA-0.89x

PEG Ratio

OTLKN/A

RNAN/A

Forward P/E (NTM)

OTLKN/A

RNAN/A

Forward P/S (NTM)

OTLK3.58x

RNAN/A

Revenue (TTM)

OTLK$-1M

RNA$41M

Revenue Growth (YoY)

OTLK-171.2%

RNA22.0%

Forward Rev Growth

OTLK26.4%

RNA-94.2%

Gross Margin (TTM)

OTLK203.8%

RNA0.0%

Operating Margin (TTM)

OTLK0.0%

RNA0.0%

EBITDA Margin (TTM)

OTLK5181.7%

RNA-215.0%

Net Margin (TTM)

OTLK5703.4%

RNA-209.2%

FCF Margin (TTM)

OTLKN/A

RNA-193.4%

Net Income (TTM)

OTLK$-61M

RNA$-86M

FCF (TTM)

OTLK$-56M

RNA$-80M

EPS (TTM)

OTLK-$0.45

RNA-$5.05

ROE (TTM)

OTLK-41551.0%

RNA-4030.0%

ROA (TTM)

OTLK-28798.0%

RNA-5864.0%

ROIC (TTM)

OTLK-16327.0%

RNA-4433.7%

Cash

OTLK$11M

RNA$72M

Debt

OTLK$18M

RNA$0

Net Cash/Debt

OTLK$-7M

RNA$72M

Current Ratio (TTM)

OTLK0.81x

RNA8.73x

Quick Ratio (TTM)

OTLK0.45x

RNA8.59x

Debt/Equity (TTM)

OTLK3.04x

RNA0.00x

Debt/Assets (TTM)

OTLK0.0%

RNA0.0%

Interest Coverage (TTM)

OTLKN/A

RNAN/A

Net Debt/EBITDA (TTM)

OTLK0.00x

RNA0.00x

Beta

OTLK0.64

RNA1.20

52W Performance

OTLK-52.5%

RNA-82.6%

YTD Performance

OTLK-9.3%

RNA-88.3%

% from 52W High

OTLK-76.4%

RNA-88.5%

% from 52W Low

OTLK271.8%

RNA10.1%

Asset Turnover (TTM)

OTLK0.01x

RNA0.28x

FCF Yield (TTM)

OTLK-50.1%

RNA-55.5%

Earnings Yield (TTM)

OTLK-54.6%

RNA-60.1%

Dividend Yield (TTM)

OTLKN/A

RNAN/A

Rule of 40

OTLK5,010.5

RNA-171.3

EV/GP/RG

OTLKN/A

RNAN/A

Ticker research

View OTLK research View RNA research

Metric	OTLK Outlook Therapeutics Inc	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$112M	$144M
Enterprise Value	$119M	$71M
Price	$0.60	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.48x
EV/Sales	1,109.27x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	13.76x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.12x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.58x	N/A
Revenue & Growth
Revenue (TTM)	$-1M	$41M
Revenue Growth (YoY)	-171.2%	22.0%
Forward Rev Growth	26.4%	-94.2%
Profitability
Gross Margin (TTM)	203.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	5181.7%	-215.0%
Net Margin (TTM)	5703.4%	-209.2%
FCF Margin (TTM)	N/A	-193.4%
Net Income (TTM)	$-61M	$-86M
FCF (TTM)	$-56M	$-80M
EPS (TTM)	-$0.45	-$5.05
ROE (TTM)	-41551.0%	-4030.0%
ROA (TTM)	-28798.0%	-5864.0%
ROIC (TTM)	-16327.0%	-4433.7%
Financial Health
Cash	$11M	$72M
Debt	$18M	$0
Net Cash/Debt	$-7M	$72M
Current Ratio (TTM)	0.81x	8.73x
Quick Ratio (TTM)	0.45x	8.59x
Debt/Equity (TTM)	3.04x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	1.20
52W Performance	-52.5%	-82.6%
YTD Performance	-9.3%	-88.3%
% from 52W High	-76.4%	-88.5%
% from 52W Low	271.8%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.28x
FCF Yield (TTM)	-50.1%	-55.5%
Earnings Yield (TTM)	-54.6%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,010.5	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View OTLK research	View RNA research

Valuation

P/S Ratio

OTLK

0.00x

RNA

3.48x

EV/FCF

OTLK

-2.12x

RNA

-0.89x

Growth & revenue

Revenue Growth TTM

RNA

22.0%

OTLK

-171.2%

Forward Revenue Growth

OTLK

26.4%

RNA

-94.2%

Profitability & performance

Gross Margin

OTLK

203.8%

RNA

0.0%

ROE

RNA

-4030.0%

OTLK

-41551.0%

FCF Yield %

OTLK

-50.1%

RNA

-55.5%

52-Week Performance

OTLK

-52.5%

RNA

-82.6%

Detailed metrics comparison

OTLK

Outlook Therapeutics Inc

RNA

Atrium Therapeutics Inc

Market Cap

OTLK$112M

RNA$144M

Enterprise Value

OTLK$119M

RNA$71M

Price

OTLK$0.60

RNA$8.40

P/E Ratio

OTLKN/A

RNAN/A

P/S Ratio

OTLK0.00x

RNA3.48x

EV/Sales

OTLK1,109.27x

RNA1.73x

EV/EBITDA

OTLK0.00x

RNA0.00x

P/B Ratio

OTLK13.76x

RNA0.63x

P/FCF Ratio

OTLKN/A

RNAN/A

EV/FCF

OTLK-2.12x

RNA-0.89x

PEG Ratio

OTLKN/A

RNAN/A

Forward P/E (NTM)

OTLKN/A

RNAN/A

Forward P/S (NTM)

OTLK3.58x

RNAN/A

Revenue (TTM)

OTLK$-1M

RNA$41M

Revenue Growth (YoY)

OTLK-171.2%

RNA22.0%

Forward Rev Growth

OTLK26.4%

RNA-94.2%

Gross Margin (TTM)

OTLK203.8%

RNA0.0%

Operating Margin (TTM)

OTLK0.0%

RNA0.0%

EBITDA Margin (TTM)

OTLK5181.7%

RNA-215.0%

Net Margin (TTM)

OTLK5703.4%

RNA-209.2%

FCF Margin (TTM)

OTLKN/A

RNA-193.4%

Net Income (TTM)

OTLK$-61M

RNA$-86M

FCF (TTM)

OTLK$-56M

RNA$-80M

EPS (TTM)

OTLK-$0.45

RNA-$5.05

ROE (TTM)

OTLK-41551.0%

RNA-4030.0%

ROA (TTM)

OTLK-28798.0%

RNA-5864.0%

ROIC (TTM)

OTLK-16327.0%

RNA-4433.7%

Cash

OTLK$11M

RNA$72M

Debt

OTLK$18M

RNA$0

Net Cash/Debt

OTLK$-7M

RNA$72M

Current Ratio (TTM)

OTLK0.81x

RNA8.73x

Quick Ratio (TTM)

OTLK0.45x

RNA8.59x

Debt/Equity (TTM)

OTLK3.04x

RNA0.00x

Debt/Assets (TTM)

OTLK0.0%

RNA0.0%

Interest Coverage (TTM)

OTLKN/A

RNAN/A

Net Debt/EBITDA (TTM)

OTLK0.00x

RNA0.00x

Beta

OTLK0.64

RNA1.20

52W Performance

OTLK-52.5%

RNA-82.6%

YTD Performance

OTLK-9.3%

RNA-88.3%

% from 52W High

OTLK-76.4%

RNA-88.5%

% from 52W Low

OTLK271.8%

RNA10.1%

Asset Turnover (TTM)

OTLK0.01x

RNA0.28x

FCF Yield (TTM)

OTLK-50.1%

RNA-55.5%

Earnings Yield (TTM)

OTLK-54.6%

RNA-60.1%

Dividend Yield (TTM)

OTLKN/A

RNAN/A

Rule of 40

OTLK5,010.5

RNA-171.3

EV/GP/RG

OTLKN/A

RNAN/A

Ticker research

View OTLK research View RNA research

Metric	OTLK Outlook Therapeutics Inc	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$112M	$144M
Enterprise Value	$119M	$71M
Price	$0.60	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.48x
EV/Sales	1,109.27x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	13.76x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.12x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.58x	N/A
Revenue & Growth
Revenue (TTM)	$-1M	$41M
Revenue Growth (YoY)	-171.2%	22.0%
Forward Rev Growth	26.4%	-94.2%
Profitability
Gross Margin (TTM)	203.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	5181.7%	-215.0%
Net Margin (TTM)	5703.4%	-209.2%
FCF Margin (TTM)	N/A	-193.4%
Net Income (TTM)	$-61M	$-86M
FCF (TTM)	$-56M	$-80M
EPS (TTM)	-$0.45	-$5.05
ROE (TTM)	-41551.0%	-4030.0%
ROA (TTM)	-28798.0%	-5864.0%
ROIC (TTM)	-16327.0%	-4433.7%
Financial Health
Cash	$11M	$72M
Debt	$18M	$0
Net Cash/Debt	$-7M	$72M
Current Ratio (TTM)	0.81x	8.73x
Quick Ratio (TTM)	0.45x	8.59x
Debt/Equity (TTM)	3.04x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	1.20
52W Performance	-52.5%	-82.6%
YTD Performance	-9.3%	-88.3%
% from 52W High	-76.4%	-88.5%
% from 52W Low	271.8%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.28x
FCF Yield (TTM)	-50.1%	-55.5%
Earnings Yield (TTM)	-54.6%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,010.5	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View OTLK research	View RNA research